Adult GlioblastomaPhase 1NCT04573140Papers
Autologous total tumor mRNA
RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
What the film says
When a malignant brain tumor returns in a child or young adult, surgery removes what is visible; the cells left behind regrow.
The idea: at surgery, seed the tumor bed with two viruses, one that kills, one that calls the immune system in.
At the University of Michigan, once the tumor is out, the surgeon injects two modified adenoviruses into the surrounding brain. One carries a herpes gene that turns the oral drug valacyclovir into a poison inside dividing tumor cells. The other carries Flt3L, which summons dendritic cells, so the dying tumor is shown to the immune system. Valacyclovir is taken two weeks per cycle.
Early safety study, ages three to thirty-nine. Andrea Franson leads it. Public record; not medical advice.
Sources behind this film
Recurrent malignant primary brain tumors after standard therapy; resectable; Two adenoviral vectors injected around the tumor at resection; HSV1-TK converts valacyclovir into a cytotoxic in dividing cells; Flt3L recruits dendritic cells; immune recognition of tumor as "invaders" (+2 more lines)
The drug
Undergo standard of care tumor resection
22MAY2026- Inclusion criteria updated to correct a typographical error regarding serum albumin.
The study
This phase I trial tests the safety, side effects and best dose of AdV-HSV1-TK and AdV-Flt3L in combination with valacyclovir for the treatment of patients with primary cancerous (malignant) brain tumors that can be removed by surgery (resectable) and that have come back after a period of improvement (recurrent).
AdV-HSV1-TK and AdV-Flt3L use a virus modified in the laboratory to kill tumor cells and stimulate the immune system to recognize the tumor cells as "invaders" which can lead to tumor shrinkage. For this process to work, an oral anti-herpes medication called valacyclovir is also needed. Giving AdV-HSV1-TK, AdV-Flt3L and valacyclovir may be safe, tolerable and/or effective in treating patients with resectable, recurrent primary malignant brain tumors.
Eligibility
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
For you, or someone you love
A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.
Then $9 a month. Cancel anytime.
Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.
Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.
Ask about your own file, and walk in with questions for your oncologist or the trial team.
Share one profile with the family helping you, and with your doctors.
Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.